Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106852706 | 10685270 | 6 | F | 20141116 | 20160906 | 20141231 | 20160909 | EXP | JP-ASTELLAS-2014JP027262AA | ASTELLAS | NIITSU Y, TAKEUCHI Y, WATANABE S, ITO K, KINNO K, SAWADA Y, ET AL.. A CASE OF PROSTATE CANCER THAT STATUS EPILEPTICUS WAS NOTED AFTER THE ADMINISTRATION OF ENZALUTAMIDE. JAPANESE JOURNAL OF UROLOGICAL SURGERY. 2016;29 (7):1194 | 83.86 | YR | M | Y | 55.00000 | KG | 20160909 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 106852706 | 10685270 | 1 | PS | XTANDI | ENZALUTAMIDE | 1 | Oral | 6240 | MG | 203415 | 160 | MG | CAPSULE | QD | |||||
| 106852706 | 10685270 | 2 | SS | CRAVIT | LEVOFLOXACIN | 1 | Oral | 1000 | MG | 0 | 500 | MG | TABLET | QD | |||||
| 106852706 | 10685270 | 3 | SS | CRAVIT | LEVOFLOXACIN | 1 | Oral | 1000 | MG | 0 | 250 | MG | TABLET | QD | |||||
| 106852706 | 10685270 | 4 | C | NEXIUM | ESOMEPRAZOLE MAGNESIUM | 1 | Oral | U | 0 | 20 | MG | CAPSULE | QD | ||||||
| 106852706 | 10685270 | 5 | C | SENNOSIDE /00571901/ | SENNOSIDES A AND B | 1 | Oral | U | 0 | 12 | MG | TABLET | QD | ||||||
| 106852706 | 10685270 | 6 | C | ADONA /00056903/ | CARBAZOCHROME SODIUM SULFONATE | 1 | Oral | UNK UNK, AS NEEDED | U | 0 | TABLET | ||||||||
| 106852706 | 10685270 | 7 | C | TRANSAMIN | TRANEXAMIC ACID | 1 | Oral | UNK UNK, AS NEEDED | U | 0 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 106852706 | 10685270 | 1 | Hormone-refractory prostate cancer |
| 106852706 | 10685270 | 2 | Urinary tract infection |
| 106852706 | 10685270 | 4 | Gastrooesophageal reflux disease |
| 106852706 | 10685270 | 5 | Constipation |
| 106852706 | 10685270 | 6 | Haematuria |
| 106852706 | 10685270 | 7 | Haematuria |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 106852706 | 10685270 | OT |
| 106852706 | 10685270 | HO |
| 106852706 | 10685270 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 106852706 | 10685270 | Haematuria | |
| 106852706 | 10685270 | Seizure | |
| 106852706 | 10685270 | Urinary tract infection | |
| 106852706 | 10685270 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 106852706 | 10685270 | 1 | 20141016 | 20141125 | 0 | |
| 106852706 | 10685270 | 2 | 20141116 | 20141117 | 0 | |
| 106852706 | 10685270 | 3 | 20141118 | 201411 | 0 | |
| 106852706 | 10685270 | 4 | 20140801 | 0 | ||
| 106852706 | 10685270 | 5 | 20140903 | 0 | ||
| 106852706 | 10685270 | 6 | 20141123 | 0 | ||
| 106852706 | 10685270 | 7 | 20141123 | 0 |